89bio, Inc. (ETNB) Covered Calls

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

You can sell covered calls on 89bio, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ETNB (prices last updated Tue 4:16 PM ET):

89bio, Inc. (ETNB) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
8.40 -0.46 7.80 9.00 657K - 0.9
Covered Calls For 89bio, Inc. (ETNB)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Jun 21 7.5 0.15 8.85 -15.3% -1396.1%
Jul 19 7.5 0.95 8.05 -6.8% -77.6%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial